Orion Oyj (OTCMKTS:ORINY) Hits New 1-Year High – What’s Next?

Orion Oyj (OTCMKTS:ORINY) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $30.57 and last traded at $30.57, with a volume of 306 shares changing hands. The stock had previously closed at $29.76.

Wall Street Analysts Forecast Growth

Separately, Nordea Equity Research lowered shares of Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

Orion Oyj Trading Up 2.7 %

The firm has a market capitalization of $8.63 billion, a P/E ratio of 24.26 and a beta of 0.25. The stock’s 50-day simple moving average is $26.95 and its two-hundred day simple moving average is $25.50. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.42 and a quick ratio of 1.41.

Orion Oyj (OTCMKTS:ORINY) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.28 earnings per share for the quarter. The business had revenue of $463.41 million during the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. Equities research analysts expect that Orion Oyj will post 1.18 EPS for the current year.

Orion Oyj Increases Dividend

The company also recently declared a dividend, which will be paid on Tuesday, April 29th. Shareholders of record on Monday, April 7th will be given a $0.4478 dividend. This is a positive change from Orion Oyj’s previous dividend of $0.24. The ex-dividend date is Monday, April 7th. Orion Oyj’s dividend payout ratio is presently 26.40%.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.